Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling

Biochemical and Biophysical Research Communications

Volumn 469, Issue 4, 2016, Pages 1133-1139

  Noda, Saori ^a,b   Takahashi, Atsushi ^a   Hayashi, Takeru ^a   Tanuma, Sei Ichi ^b   Hatakeyama, Masanori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

LEOPARD syndrome; Noonan syndrome; Parafibromin CDC73; Protein tyrosine phosphatase; SHP2 PTPN11; Wnt signal

Indexed keywords

BCR ABL PROTEIN; PARAFIBROMIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; CDC73 PROTEIN, HUMAN; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; ESCHERICHIA COLI; EXPRESSION VECTOR; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEOPARD SYNDROME; MISSENSE MUTATION; NONHUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; WILD TYPE; WNT SIGNALING PATHWAY; ANIMAL; CATALYSIS; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; ENZYME ACTIVATION; ENZYME SPECIFICITY; GENETICS; METABOLISM; MUTATION;

ANIMALS; CATALYSIS; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME ACTIVATION; HUMANS; LEOPARD SYNDROME; MUTATION; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEINS; WNT SIGNALING PATHWAY;

EID: 84957851977     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.12.117     Document Type: Article

References (30)

1. S. Jakob, P. Schroeder, M. Lukosz, and et al. Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase J. Biol. Chem. 283 2008 33155 33161
2. A. Takahashi, R. Tsutsumi, I. Kikuchi, and et al. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver Mol. Cell 43 2011 45 56
3. B.G. Neel, H. Gu, and L. Pao The "Shp"ing news: SH2 domain-containing tyrosine phosphatases in cell signaling Trends Biochem. Sci. 28 2003 284 293
4. T. Brummer, D. Schramek, V.M. Hayes, and et al. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein J. Biol. Chem. 281 2006 626 637
5. R. Tsutsumi, M. Masoudi, A. Takahashi, and et al. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function Dev. Cell 26 2013 658 665
6. C. Mosimann, G. Hausmann, and K. Basler Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with β-catenin/Armadillo Cell 125 2006 327 341
7. G. Chan, D. Kalaitzidis, and B.G. Neel The tyrosine phosphatase Shp2 (PTPN11) in cancer Cancer Metastasis Rev. 27 2008 179 192
8. M. Tartaglia, B.D. Gelb, and M. Zenker Noonan syndrome and clinically related disorders Best. Pract. Res. Clin. Endocrinol. Metab. 25 2011 161 179
9. A. Sarkozy, M. Digilio, and B. Dallapiccola Leopard syndrome Orphanet J. Rare Dis. 3 2008 13
10. M. Tartaglia, E.L. Mehler, R. Goldberg, and et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome Nat. Genet. 29 2001 465 468
11. M.I. Kontaridis, K.D. Swanson, F.S. David, and et al. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects J. Biol. Chem. 281 2006 6785 6792
12. T.M. Marin, K. Keith, B. Davies, and et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation J. Clin. Invest 121 2011 1026 1043
13. D. Miyamoto, M. Miyamoto, A. Takahashi, and et al. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors Oncogene 27 2008 3508 3515
14. L. Nagase, T. Hayashi, T. Senda, and et al. Dramatic increase in SHP2 binding activity of Helicobacter pylori Western CagA by EPIYA-C duplication: its implications in gastric carcinogenesis Sci. Rep. 5 2015 15749
15. Y.M. Agazie, and M.J. Hayman Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates J. Biol. Chem. 278 2003 13952 13958
16. C. Blanchetot, M. Chagnon, N. Dube, and et al. Substrate-trapping techniques in the identification of cellular PTP targets Methods 35 2005 44 53
17. Z.H. Yu, J. Xu, C.D. Walls, and et al. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations J. Biol. Chem. 288 2013 10472 10482
18. Z. Zhao, R. Larocque, W.T. Ho, and et al. Purification and characterization of PTP2C, a widely distributed protein tyrosine phosphatase containing two SH2 domains J. Biol. Chem. 269 1994 8780 8785
19. M. Tartaglia, S. Martinelli, L. Stella, and et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease Am. J. Hum. Genet. 78 2006 279 290
20. S. Martinelli, P. Torreri, M. Tinti, and et al. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes Hum. Mol. Genet. 17 2008 2018 2029
21. N. Hanna, A. Montagner, W.H. Lee, and et al. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1 FEBS Lett. 580 2006 2477 2482
22. T. Edouard, J.P. Combier, A. Nedelec, and et al. Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3 signaling Mol. Cell. Biol. 30 2010 2498 2507
23. P. Smpokou, D.J. Zand, K.N. Rosenbaum, and et al. Malignancy in Noonan syndrome and related disorders Clin. Genet. 88 2015 516 522
24. S.Q. Zhang, W.G. Tsiaras, T. Araki, and et al. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2 Mol. Cell. Biol. 22 2002 4062 4072
25. D.R. Mattoon, B. Lamothe, I. Lax, and et al. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway BMC Biol. 2 2004 24
26. C. Schramm, D.M. Fine, M.A. Edwards, and et al. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling Am. J. Physiol. Heart Circ. Physiol. 302 2012 H231 H243
27. C.M. Alfieri, J. Cheek, S. Chakraborty, and et al. Wnt signaling in heart valve development and osteogenic gene induction Dev. Biol. 338 2010 127 135
28. Y. Chen, and B.A. Alman Wnt pathway, an essential role in bone regeneration J. Cell Biochem. 106 2009 353 362
29. K. Takahashi, S. Kogaki, S. Kurotobi, and et al. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy Eur. J. Pediatr. 164 2005 497 500
30. M. Ganigara, A. Prabhu, and R.S. Kumar LEOPARD syndrome in an infant with severe hypertrophic cardiomyopathy and PTPN11 mutation Ann. Pediatr. Cardiol. 4 2011 74 76